Notifications
Clear all
Topic starter 06/02/2022 3:02 pm
Hello, everyone! In radioimmune therapy are used, in particular, antibodies labeled with radioactive isotopes of metal or of halogenes. From the point of view of therapeutic efficiency, the usage of metal isotopes is more advantageous than the usage of halogen isotopes, since malignant tumors absorb much more radiopharmaceuticals containing metal isotopes. Meanwhile, in practice, preference is given to antibodies labeled with halogens (most often with iodine). Why is it so?
This topic was modified 2 years ago by morphism
07/02/2022 9:42 pm
Hi! Yes, indeed, malignant tumors are more fond of antibodies labeled with isotopes of mettals. But at the same time, such antibodies accumulate more strongly in the liver and kidneys, which can cause extremely undesirable consequences
08/02/2022 8:57 pm
@_brauer_ in addition, iodine is excreted in the urine, while many metals are excreted through the gallbladder
